Neuphoria Therapeutics Inc. Proceeds from Warrant Exercises
Neuphoria Therapeutics Inc. (NEUP) reported Proceeds from Warrant Exercises of $409 for the 3-month period ending 2024-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromWarrantExercises · last filed 2025-11-14
- Neuphoria Therapeutics Inc. proceeds from warrant exercises for the quarter ending 2024-09-30 was $409.00.
- Neuphoria Therapeutics Inc. proceeds from warrant exercises for the quarter ending 2023-09-30 was $0.00.
| Period end | Proceeds from Warrant Exercises 3 month |
|---|---|
| 2024-09-30 | $409.00 10-Q · filed 2025-11-14 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |